Response to: Correspondence on "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation" by Braaten
et al
Ann Rheum Dis
.
2022 Jan;81(1):e14.
doi: 10.1136/annrheumdis-2019-216892.
Epub 2020 Jan 20.
Authors
Laura C Cappelli
1
,
Clifton O Bingham
2
,
Tawnie Braaten
3
,
Ami A Shah
2
Affiliations
1
Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA lcappel1@jhmi.edu.
2
Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
3
Rheumatology, University of Utah, Salt Lake City, Utah, USA.
PMID:
31959594
PMCID:
PMC7369218
DOI:
10.1136/annrheumdis-2019-216892
No abstract available
Keywords:
arthritis; autoimmunity; inflammation.
Publication types
Letter
Comment
MeSH terms
Arthritis*
Humans
Immune Checkpoint Inhibitors*
Immunologic Factors
Immunotherapy / adverse effects
Substances
Immune Checkpoint Inhibitors
Immunologic Factors
Grants and funding
K23 AR075872/AR/NIAMS NIH HHS/United States